about
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining f...
Read More
17.17
-0.22
(-1.27%)
19.9M
XNAS Volume
XNAS 08 May, 2026 5:30 PM (EDT)
Rising Revenue
Viatris' Q1 revenue jumps 8% YoY to $3.5 bn, driven by new product launches and sales in China
See details
Not Eligible
Expensive Valuation
Technically Bullish
Viatris Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..